Summit Therapeutics PLC
$ 22.08
-0.85%
24 Apr - close price
- Market Cap 17,283,301,000 USD
- Current Price $ 22.08
- High / Low $ 22.36 / 21.45
- Stock P/E N/A
- Book Value 0.85
- EPS -1.44
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.15 %
- ROE -2.06 %
- 52 Week High 30.98
- 52 Week Low 13.83
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$30.96
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-10-28 | 2025-08-11 | 2025-04-29 | 2025-02-24 | 2024-10-30 | 2024-08-06 | 2024-05-01 | 2024-02-20 | 2023-11-07 | 2023-08-09 | 2023-05-11 |
| Reported EPS | -0.3908 | -0.2315 | -0.12 | -0.0677 | -0.07 | -0.08 | -0.09 | -0.06 | -0.04 | -0.03 | -0.02 | -1.43 |
| Estimated EPS | -0.08 | -0.1032 | -0.09 | -0.0682 | -0.08 | -0.07 | -0.06 | -0.06 | -0.05 | None | None | -1.43 |
| Surprise | -0.3108 | -0.1283 | -0.03 | 0.0005 | 0.01 | -0.01 | -0.03 | 0 | 0.01 | 0 | 0 | 0 |
| Surprise Percentage | -388.5% | -124.3217% | -33.3333% | 0.7331% | 12.5% | -14.2857% | -50% | 0% | 20% | None% | None% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.33 |
| Currency | GBP |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SMMT
2026-04-25 08:38:57
Eighteen analysts have given Summit Therapeutics (NASDAQ:SMMT) a consensus "Moderate Buy" rating, with an average 12-month price target of $31.00. Recent analyst activity includes new "buy" ratings from Stifel and Citigroup, while HC Wainwright adjusted its target to $30.00 and Zacks upgraded the stock to "hold". Despite missing its last EPS estimate, the company's shares are trading around $22.08, with a market capitalization of $17.14 billion.
2026-04-23 13:38:57
Investors recently bought a significantly higher volume of call options for Summit Therapeutics (NASDAQ:SMMT), with 16,625 call options traded, a 387% increase from the typical volume. This indicates a strong bullish sentiment, despite the company's recent earnings miss and a stock price drop on high volume. Analyst ratings for SMMT are mixed, ranging from "sell" to "strong buy," with a consensus of "Moderate Buy" and an average price target of $31.00.
2026-04-23 01:10:03
Summit Therapeutics (NASDAQ:SMMT) saw its shares drop 6.2% to $24.74 on Wednesday, with trading volume significantly below average. The company missed quarterly EPS estimates, and its analyst coverage is mixed, ranging from "Strong Buy" to "Sell," with an average price target of $31.00. Despite the recent dip and missed earnings, the company's lead drug, ridinilazole, has Fast Track and QIDP designations, and institutional investors have recently increased their stakes.
2026-04-22 01:10:03
Summit Therapeutics (NASDAQ:SMMT) experienced a significant surge in trading volume, with shares up 81% from the previous session. The stock closed at $26.0280, up from $25.12, despite the company reporting a wider-than-expected quarterly loss of ($0.29) EPS. Analyst ratings are mixed, leading to a "Moderate Buy" consensus and a target price of $31.00.
2026-04-21 17:09:05
Stifel has reiterated a Buy rating and a $45.00 price target for Summit Therapeutics (NASDAQ:SMMT) following the disclosure of HARMONi-6 interim Overall Survival readout data. The stock has seen a significant year-to-date increase, partly due to expectations from upcoming trial results. Other analysts like UBS and Cantor Fitzgerald also maintain Buy/Overweight ratings, while Jefferies downgraded to Hold due to perceived risks.
2026-04-20 07:39:25
This article mentions that Summit Therapeutics possesses scarcity value in the competitive drug development landscape, according to an unnamed analyst. The content provided is minimal, only stating the title and a time of publication.
